Navigation Links
Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
Date:11/12/2009

tate cancer, and Triolex, in a Phase IIa trial in obese Type 2 diabetes patients. Apoptone and Triolex represent the lead candidates from Hollis-Eden's small molecule platform based on metabolites or synthetic analogs of endogenous steroid hormones. For more information on Hollis-Eden please visit www.holliseden.com.

This press release contains forward-looking statements within the meaning of the federal securities laws concerning, among other things, the presentation of the results of Hollis-Eden Pharmaceuticals, Inc. ongoing human clinical Phase I/II open-label dose-ranging trial with Apoptone (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC) on November 16; the completion of Hollis-Eden's Phase II trial (HE3286-0401) in obese, insulin-resistant diabetic patients in the first quarter of 2010; the continuation of Hollis-Eden's operations focused on its lead programs into the latter half of 2010; Hollis-Eden's use of data from its ongoing trials to engage with potential corporate partners for the design and funding of late-stage development programs; and Hollis-Eden's ability to conduct proof-of-concept trials in other diseases with an auto-immune inflammatory etiology as resources become available. Any statement included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause Hollis-Eden's actual results to differ materially from historical results or those expressed or implied by such forward-looking statements. Such statements are subject to certain risks and uncertainties inherent in the Company's business, including, but not limited to: the ability to complete preclinical and clinical trials successfully and within spe
'/>"/>

SOURCE Hollis-Eden Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price
2. Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
3. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
4. NeoGenomics To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 18, 2009
5. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
6. Viron to Present Data from Phase II Trial at American Heart Association Conference
7. Curemark Presents at Springboard Enterprises Life Sciences Forum
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16, 2009
9. NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009
10. CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response
11. Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... conjugates for cancer, today announced the appointment of Thomas C ... has over 20 years, development experience gained in the biotechnology ... "I am delighted to welcome Tom at this ...
(Date:1/15/2014)... , January 15, 2014 A study has ... on the Formula 1 track could help to tackle the ... Technologies (MAT), Stowhealth (a GP surgery based in Stowmarket) and ... provider Simplyhealth. Telemetry technology, which is inspired by ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent ... viruses is the Epstein Barr Virus (EBV), and one of ... a chronic inflammatory disease that destroys the body’s joints. As ... have high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... do Dr. Peper, Dr. Sigmund Freud and Arnold Schwarzenegger ... be surprised to learn that Europeans love Dr. Peper. ... Erik Peper, President of the Biofeedback Foundation of Europe ... Dr. Erik Peper opens the 13th Annual Conference of ...
... Presents on Therapy Development StrategyCAMBRIDGE, Mass., Feb. 17 ... has announced the 2009 launch of its popular ... seminar is designed to inform and update patients, ... to discover and develop effective treatments for amyotrophic ...
... Inc. (OTC Bulletin Board: GNPH) ("Genesis" or the,"Company"), a ... Republic of China, today announced its financial results for ... 31, 2008. , , Second Quarter ... Revenue was $32.9 million, up 24.1% from the corresponding ...
Cached Biology Technology:Dr. Peper, Dr. Freud and Arnold Schwarzenegger 2Seminar Will Bring ALS Researchers to Patient Groups 2Seminar Will Bring ALS Researchers to Patient Groups 3Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 2Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 3Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 4Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 5Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 6Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 7Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 8Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 9Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 10Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 11Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 12Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 13Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 14Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 15Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 16
(Date:4/17/2014)... April 17, 2014The development of stem cell therapies to ... to characterize stem cell populations based on cell surface ... a new marker that is highly expressed in a ... blood, which they describe in an article in ... Ann Liebert, Inc., publishers. The article is available free ...
(Date:4/17/2014)... Marc Andr Gauthier and Professor Luca Razzari of ... been awarded large grants from the John R. ... Innovation (CFI) for the acquisition of state-of-the-art biotech ... added matching grants from the Ministre de l,Enseignement ... de la Technologie (MESRST). These new laboratories will ...
(Date:4/17/2014)... news release is available in German . ... us to recognise objects; they also provide us with a ... run, turn around, fall or sit still in a car ... motion trace on our retinas. Seemingly without effort, our brain ... maintain a stable position and a steady gaze during our ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4
... NARRAGANSETT, RI -- June 7, 2011 -- Sunshine Menezes, executive ... and 2010 Grantham Prize winner Alanna Mitchell announced the 2011 ... the Environment. James Astill of The Economist will receive US$75,000 ... a commanding 8-part special report on the state of global ...
... in billionths of a meter, self-assembling nano-sized devices designed ... are revolutionizing medicine by improving drug solubility and bio-distribution, ... and enabling membrane barriers to be crossed as well ... Self-assembling nano devices are now enlisted in the ...
... turns out, humans aren,t the only organisms that turn to ... four different bacteria that actually can live on caffeine. ... was found in a flowerbed outside a UI research laboratory. ... understanding of how the process works -- could in the ...
Cached Biology News:$75,000 Grantham Prize winner announced 2$75,000 Grantham Prize winner announced 3Super-mini vehicles carry therapeutics and imaging agents into body with mega results 2University of Iowa researchers identify caffeine-consuming bacterium 2
DryStrip aligners, 4. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
...
...
Antibodies were affinity purified using epitopes specific to QKI immobilized on solid support....
Biology Products: